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Abstract
Background: Mood disorders represent the most expensive mental disorders for employer-based commercial health
plans. Collaborative care models are effective in treating chronic physical and mental illnesses at little to no net healthcare
cost, but to date have primarily been implemented by larger healthcare organizations in facility-based models. The
majority of practices providing commercially insured care are far too small to implement such models. Health plan-level
collaborative care treatment can address this unmet need. The goal of this study is to implement at the national
commercial health plan level a collaborative care model to improve outcomes for persons with mood disorders.
Methods/Design: A randomized controlled trial of a collaborative care model versus usual care will be conducted
among beneficiaries of a large national health plan from across the country seen by primary care or behavioral health
practices. At discharge 344 patients identified by health plan claims as hospitalized for unipolar depression or bipolar
disorder will be randomized to receive collaborative care (patient phone-based self-management support, care
management, and guideline dissemination to practices delivered by a plan-level care manager) or usual care from their
provider. Primary outcomes are changes in mood symptoms and mental health-related quality of life at 12 months.
Secondary outcomes include rehospitalization, receipt of guideline-concordant care, and work productivity.
Discussion: This study will determine whether a collaborative care model for mood disorders delivered at the national
health plan level improves outcomes compared to usual care, and will inform a business case for collaborative care
models for these settings that can reach patients wherever they receive treatment.
Trial registration: ClinicalTrials.gov Identifier: NCT02041962; registered January 3, 2014.
Keywords: Depression, Health behavior change, Care management, Health plans
Background
A recent report from the Department of Health and
Human Services highlighted the prevalence, morbidity,
and cost associated with clusters of co-occurring chronic
conditions, both physical and mental (U.S. Department of
Health and Human Services 2011). Evidence suggests that
collaborative care models (CCMs) are effective in treating
chronic medical and mental illnesses at little to no net
healthcare cost (A National Agenda for Research in
Collaborative Care. June 2011; Woltmann et al. 2012;
Bodenheimer et al. 2002; Wagner et al. 1996; Coleman
et al. 2009a). CCMs typically consist of patient self-
management skill enhancement, expert decision sup-
port to providers via evidence-based practice guidelines,
and enhanced access and continuity via care managers
(Bauer 2001; Bauer et al. 2001). CCMs will become in-
creasingly important as healthcare delivery systems evolve
into accountable care organizations (Fisher et al. 2009;
Shortell & Casalino 2010), thereby taking on broader re-
sponsibility for care coordination and quality while bear-
ing financial risk for complex, chronic conditions. CCMs
can provide either the foundation of, or an annex to,
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et al. 2009; Carrier et al. 2009; Rittenhouse et al. 2008).
To date, evidence-based CCMs have primarily been
implemented at the facility level in publically funded set-
tings (A National Agenda for Research in Collaborative
Care. June 2011; Woltmann et al. 2012; Coleman et al.
2009b; Collins et al. 2010) or within integrated health-
care systems (Rittenhouse et al. 2010; Casalino et al.
2003; Druss et al. 2010; Katon et al. 2010) but not in
smaller practices (Bauer et al. 2012a). However, the ma-
jority (between 50-70%) of patients receive care from
network-model health plans and within small practices
of less than 20 providers (Bauer et al. 2012a; Findlay
1999). These smaller practices are less likely to be able
to implement care management processes (Rittenhouse
et al. 2011). The few trials involving CCMs delivered re-
motely (off-site) recommend a combination of rapport-
building telephone care manager-patient contacts and
personally tailored self-management resources (Datto
et al. 2003; Hunkeler et al. 2000; Ludman et al. 2007a;
Lynch et al. 2004; Mohr et al. 2005; Oslin et al. 2003;
Ransom et al. 2008; Simon et al. 2000; Simon et al. 2009;
Stein et al. 2007; Tutty et al. 2005; Lynch et al. 1997;
Pariser & O'Hanlon 2005).
The goal of this study is to implement at the national
level through a commercial health plan a CCM that is
designed to improve outcomes for persons with mood
disorders. Mood disorders represent optimal tracer con-
ditions with which to improve management strategies
using CCMs for individuals with multiple chronic condi-
tions. Chronic mood disorders (e.g., bipolar disorder, de-
pression) are common and are associated with extensive
functional impairment, medical comorbidity, and per-
sonal and societal costs (Bauer 2008). National studies of
the U.S. population estimate the lifetime prevalence for
bipolar spectrum disorders as 6.4% (Judd & Akiskal
2003; Merikangas et al. 2007) and 16.6% for major de-
pressive disorder (Kessler & Wang 2008). Quality of care
is suboptimal for both chronic medical (Institute of
Medicine 2003; Lopez & Murray 1998) and mental
(Boardman 2006; Busch et al. 2004; Druss et al. 2000;
Druss et al. 2002; Hogan 2003; Leslie & Rosenheck 2004;
Leslie & Rosenheck 2003; Sernyak et al. 2003) disorders,
underscoring the need for coordinated, comprehensive
care. While unipolar depression is more common, pa-
tients with bipolar disorder incur the most health care
costs of any mental illness (Peele et al. 2003). Up to 70%
of direct treatment costs for mood disorders are gener-
ated outside the mental health sector, notably in primary
care (Bryant-Comstock et al. 2002; Simon & Unutzer
1999; Dilsaver 2011). In response to extremely high costs
and high disease burden associated with mood disorders,
CCMs have been found to be effective in reducing symp-
tom burden and improving health-related quality of life
for depression (Woltmann et al. 2012; Gilbody et al.
2006; Badamgarav et al. 2003; Unutzer et al. 2008) and
bipolar disorder (Bauer 2001; Bauer et al. 2001; Bauer et al.
2006a; Bauer et al. 2006b; Kilbourne et al. 2008; Simon
et al. 2006) in separate studies and are now recommended
in practice guidelines (American Psychiaric Association
2002; Yatham et al. 2009).
Aims and objectives
The primary aim of this study is to determine whether
individuals with mood disorders from practices treated
with a health plan-level CCM demonstrate improved
health outcomes in 12 months compared to those who
receive usual care.
Our primary hypotheses are that compared to usual
care, the CCM will result in 1) decreased mood symp-
toms in 12 months based on the nine-item Patient
Health Questionnaire (PHQ-9), or 2) improved mental
health-related quality of life based on the Short Form
Health Survey (SF-12). Our secondary hypotheses are
that patients receiving CCM versus usual care will have
1) reduced probability of hospitalization, 2) improved
guideline-concordant care (e.g., mood disorders treatment,
cardiometabolic monitoring), and 3) improved work prod-
uctivity within 12 months.
Exploratory aims of this study are to support subse-
quent CCM dissemination by identifying key patient
characteristics associated with CCM engagement and
outcomes, to estimate the costs of CCM versus usual
care, and assess the incremental costs per difference in
patient-level utility associated with CCM versus usual
care over a 24-month period.
Methods
This single-blind randomized controlled effectiveness
trial will compare patients receiving the CCM for mood
disorders versus usual care. The population of interest
will be Aetna adult enrollees and family members (benefi-
ciaries) across the country hospitalized for an episode of
unipolar depression or bipolar disorder. The University of
Michigan Medical School Institutional Review Board ap-
proved this study with a waiver of documentation of writ-
ten consent (IRBMED HUM00073753) and the study was
registered with ClinicalTrials.gov on January 3, 2014
(NCT02041962). All participants will provide verbal in-
formed consent to the Aetna care manager, and will re-
ceive a mailed copy of the consent for their records.
Setting
The CCM will be implemented by providers employed
at Aetna Behavioral Health for beneficiaries from across
the country who are hospitalized for depression or bipo-
lar disorder. Aetna health plan is the fifth largest health-
care insurer in the country, providing benefits through
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covered lives, with 244,971 providers filing claims within
the past year, Aetna Behavioral Health has made the devel-
opment and implementation of CCMs a top priority.
Among its enrollees, over 90% were seen in solo or small
practices of less than 4 providers (Bauer et al. 2012b).
Participant selection
The Aetna care manager will recruit participants by first
screening and consenting them based on near-real time
information of recent hospitalizations. At hospitalization,
Aetna is notified for (pre)authorization, typically before or
within 48 hours of admission. The care manager will be
notified about patient hospitalizations via the Aetna care
management registry and will contact the potential partici-
pant by phone, screen for eligibility, and obtain informed
consent and authorization to release information to the
research team and to coordinate care with their providers.
Because patients have not been randomized at this point,
Aetna care managers will be blind to treatment assign-
ment at baseline.
Patient inclusion criteria as determined by the care
managers include:
a. Adult patients age 21 years or older from the
contiguous United States (lower 48 states)
b. Currently covered by Aetna’s HMO or preferred
provider products (for whom Aetna provides mental
and medical inpatient, outpatient, and pharmacy
benefits) for at least 6 months
c. Recent (past 6-month) hospitalization for an acute
psychiatric or partial hospital unit with a manic or
depressive episode and confirmation of mood
disorder diagnosis in the medical record (presence of
one inpatient or two outpatient designated by
International Classification of Diseases, Ninth Revision,
Clinical Modification (ICD-9-CM) diagnostic codes:
296.1×—296.8× in previous 6 months) (Kilbourne
et al. 2008).
d. Ability to speak and read English and provide
informed consent.
Study design and randomization
As displayed by the Consort diagram in Figure 1, patients
will be randomized to CCM or usual care using a computer
generated algorithm that will stratify randomization by
diagnosis at hospitalization discharge (unipolar disorder, bi-
polar disorder). The Care Manager, prior to randomization,
will ascertain baseline information from enrolled and eli-
gible patients via a brief survey (see Outcomes section
below for questions). Remaining outcomes assessments will
be completed by a separate research assistant who is not
employed by the health plan, and will also be blinded to
randomization assignment. The Care Manager will be
trained to conduct baseline assessments by study staff on
initiating calls across time zones and in human subjects risk
reduction procedures used in prior studies (Bauer et al.
2001; Bauer et al. 2006a) that will minimize risk while not
compromising study internal validity (Bauer et al. 2001).
Intervention
Patients randomized to the usual care arm will receive
standard care from their practice provider, but none of
the CCM components from the plan-level care manager.
Patients randomized to the intervention will receive
the plan-level CCM in addition to their usual care from
their provider. The CCM intervention will be delivered
over a twelve-month period, and include an initial con-
tact with patient enrolled in the CCM arm, 10 weekly
self-management sessions, ongoing care management,
and dissemination of guidelines and follow-up with pa-
tients’ principal healthcare providers regarding clinical
issues.
The CCM is based on the Life Goals Collaborative
Care program (Table 1), which was found in several ran-
domized controlled trials to improve physical and mental
health outcomes for persons with mood disorders (3). Life
Goals Collaborative Care components delivered by the
Care Manager include the Life Goals self-management
program, care management via ongoing contacts to facili-
tate flow of current clinical status information between
patients and their principal healthcare providers, and dis-
semination of evidence-based clinical practice guidelines
for mood disorders to the providers.
The Life Goals self-management program includes
psychoeducation based on Social Cognitive Theory, em-
phasizing brief Motivational Interviewing and cognitive-
behavioral techniques, particularly behavioral activation, to
address symptom management and problem-solving skills.
Ten core modules (see Table 1) will be delivered over 10
weekly telephonic sessions of 30 minutes (Ludman et al.
2007a; Ludman et al. 2007b). The care manager will deliver
the 10 Life Goals self-management program modules via
telephone and using a workbook mailed to patients that
contains modules, exercises, and other information on
mood disorders (Kilbourne et al. 2008; Bauer et al. 2008).
For patients with bipolar disorder, at least one of the
modules will focus on coping with manic symptoms,
while patients with unipolar depression will also receive
an additional module on depressive symptoms (Ludman
et al. 2007b).
The care management calls with patients will con-
t i n u eo nam o n t h l yb a s i sf o ru pt oay e a ra f t e rt h es e l f -
management phone sessions are completed, with as-needed
phone contacts made to follow up in the event of a
hospitalization or emergency room visit. Imminent risk
(suicidal or assaultive ideation, significant medication
toxicity) will be managed via protocols used in prior
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et al. 2008). The care manager will also contact the pa-
tients’ providers on an as needed basis such as in the
event of hospitalization, emergency room visit, or devel-
opment of a new clinical issue, as well as to cue them if
there is a crisis encounter (e.g., suicidality). It is import-
ant to note that, as in our prior studies (Bauer et al.
2006a; Bauer et al. 2006b; Kilbourne et al. 2008; Simon
et al. 2006; Bauer et al. 1997), the CCM is designed to
supplement care and does not replace or control pro-
vider decision-making. Clinical decision-making re-
mains in the hands of the provider. The CCM therefore
enhances care processes by: (a) enhancing patient skills
to facilitate treatment participation, (b) offering the pro-
vider timely information, and (c) outlining situation-
specific evidence-based treatment options.
Fidelity to the CCM will be maximized via a 2-day
training session for the care manager, as well as regu-
lar ongoing calls with the care manager and training
to review enrollment progress and review session con-
tent delivered to patients randomized to the CCM.
Measures and outcomes
Baseline and outcomes data will be ascertained from
patients (including surveys, medical record reviews,
and claims data) (Table 2). A 30-minute quantitative
survey will be used to ascertain information from pa-
tients at baseline, 6, 12, 18, and 24 months thereafter.
Patient data will be entered into a web-based data man-
agement system. The baseline assessment will include a
brief survey on demographics and baseline outcomes
measures for mood symptoms, quality of life, and
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Figure 1 Consort flow diagram.
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will include questions on mood symptoms, quality of
life, and employment and work productivity. There is
the possibility that enrolled patients may inadvertently
disclose their randomization status with the RA, and
this will be mitigated through RA training (e.g., minim-
izing leading questions that would disclose treatment
assignment).
Primary outcomes include changes in mood symptoms
and mental health-related quality of life to be ascertained
between baseline and 12 months later from the patient
surveys. The surveys include the 9-item Patient Health
Questionnaire (PHQ-9) (Kroenke et al. 2001; Spitzer et al.
1999) to assess mood symptoms, and health-related qual-
ity of life based on the SF-12 Mental and Physical Health
Component Scores (MCS/PCS) (Ware et al. 1996).
Table 1 Mood disorders CCM core elements
Life goals self-management
program
10 weekly 30-min telephonic sessions utilizing the Life Goals program that include core modules
covering management of depressive symptoms and additional modules utilized as clinically indicated
(e.g., mania, wellness, foods and moods, physical activity, substance use, anxiety, psychosis, anger/irritability):
Week 1: Introduction – Understanding your mental health and stigma
Week 2: Introduction (Continued) – Personal values and Life Goals
Week 3: Identifying personal symptoms of depression
Week 4: Identifying triggers and responses to depression
Week 5: Development of personal action plan for coping with depression
Week 6: Optional Session 1
Week 7: Optional Session 2
Week 8: Optional Session 3
Week 9: Managing Your Care – Provider visit preparation
Week 10: Plan for continuing to work toward your Life Goals
Access/continuity/care
management
12 monthly patient telephone contacts for 1 year (in addition to the self-management program)
to trouble-shoot self-management issues and summarize clinical status
￿ Ad hoc contacts at either care manager or participant initiation based on clinical or other concerns,
including response to participants within one business day
￿“ In-reach” to treating clinicians for hospitalization, ER visits, or specialty consultation
￿ Collaboration with family as permitted
￿ Resource referral as needed
Provider decision support Provider contacts
￿ Same content as clinic-based CCM
￿ Guidelines disseminated where appropriate based on AHRQ depression in primary care and APA bipolar guidelines
Table 2 Primary and secondary outcomes and measures
Aims Key measures Source
Aim 1. primary outcomes Mood symptoms: PHQ-9 Patient survey
Mental health-related quality of life-SF-12 (MCS) Patient survey
Aim 1. secondary outcomes Hospitalizations Aetna claims data
Guideline concordant care: Medical record/claims
Mood disorders: % receiving guideline-concordant antidepressants
(if unipolar depression) or guideline-concordant anti-manic treatment
(bipolar disorder dx) in 6-month period
Cardiometabolic monitoring: % receiving lipid profile, fasting glucose
or HbA1C, blood pressure, and weight
Productivity (Work Limitations Questionnaire) Patient survey
Aim 2 Patient demographics Patient survey
Patient comorbidities Medical record
Aim 3: CCM costs, patient inpatient, outpatient, ER, Rx use Medical record/claims data
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plan medical records, claims files, as well as the patient
surveys (Table 2). Inpatient hospitalizations (including
length of stay) and ER use will be ascertained from Aetna
claims data. For hospitalizations, Agency for Healthcare
Research and Quality definitions of ambulatory care–sen-
sitive conditions, (http://archive.ahrq.gov/data/safetynet/
index.html) will also be used to identify hospitalizations
considered preventable.
Measures of guideline-concordant care will be ascer-
tained from Aetna electronic medical and claims records
based on diagnostic and treatment codes for medical and
psychiatric conditions, as well as utilization, labs, and
medication data from a year prior to and up to 24 months
after enrollment. Guideline-concordant care measures in-
clude previously established metrics for measuring pro-
cesses of care for mood disorders (Bauer et al. 2009;
STABLE: STAndards for BipoLar Excellence. A perform-
ance measurement and quality improvement program; 42
CFR Part 425. Medicare Program) as well as indicators
from the Accountable Care Organization published rules
for performance measures and shared savings (42 CFR
Part 425. Medicare Program) (Table 2).
Health care costs will be ascertained from the health
plan’s electronic record reviews using a standard assess-
ment tool from the enrollment date to 24 months later
(Kilbourne et al. 2010). Cost data will be estimated for
each inpatient, ER, and outpatient visit using Current
Procedural Terminology (CPT) codes. A relative value
unit (RVU) weight will allow for the use of the Medicare
Fee Schedule to calculate a standardized cost for each ser-
vice. Costs incurred in different years will be discounted at
an annual rate of 3% and adjusted for inflation and dis-
counted to the baseline (first) year of the study. Preventable
hospitalizations over the 12 and 24-month period will be
defined using the AHRQ Ambulatory Care Sensitive Con-
dition (ACSC) definition (Prevention Quality Indicators
Overview), which identifies conditions for which “good”
outpatient care can potentially prevent the need for
hospitalization or for which early intervention can prevent
complications or more severe disease.
Analyses
An intent-to-treat analysis will be performed for all ana-
lyses. Bivariate baseline analyses will first be conducted
to see if randomization was successful by comparing pa-
tient demographics and clinical characteristics (e.g.,
mental health diagnoses) between randomization groups.
If there is a lack of equal distribution across groups,
these variables will be added as covariates to analyses or
propensity scoring will be used. Baseline characteristics
will be compared among those enrolled but dropped out
over time to those who remained in the study.
Extent and pattern of missing data will be examined
for outcome variables as well as for baseline covariates.
We expect missing data to be completely at random or at
random, in which case the proposed analytical methods
will give unbiased estimates of treatment comparison. We
will examine how sensitive our conclusions are to poten-
tial non-ignorable missingness using a pattern mixture
model that will allow us to either model the observed pat-
tern of missingness or change the imputations to repre-
sent the likely differences in conditional distributions
between observed and missing data (Diggle & Kenward
1994; Little & Rubin 1987). For the latter, we will combine
the results from each imputed data using Rubin’sr u l e s
(Rubin 1987).
Changes in primary outcomes from baseline to
12 months later (mood symptoms, quality of life) will be
treated as continuous variables. Based on pilot data,
these outcome measures are expected to be normally
distributed. If a continuous outcome exhibits a signifi-
cant lack of normality, other options will be considered
including data transformation, categorization, and non-
parametric analyses. We will first visualize the longitudin-
ally assessed outcome data, including plots of cross-
sectional means of outcome variables over time. Separate
linear mixed-effects models will be run to assess the CCM
effects compared to usual care on changes in PHQ-9 and
SF-12 MCS scores over 6 and 12-months, adding as covar-
iates the baseline values of the outcome measure, the
CCM arm indicator, time, and CCM X time interaction. If
CCM by time interaction is not significant, CCM effect av-
eraged over 6 and 12 months will be obtained. Although
we expect most study participants will be under the care
of one unique provider, the model will account for poten-
tial clustering by providers as needed.
For guideline hospitalization and guideline-concordant
care, the likelihood of hospitalization (and separately for
hospitalizations involving ambulatory care sensitive condi-
tions) and receipt of guideline-concordant treatment from
baseline up to 12 months will be determined using a gen-
eralized linear mixed-effects model (GLM) with logit link.
Similar to our primary hypotheses, linear mixed-effects
models will be conducted to determine the effect of CCM
versus usual care on changes in the Work and Social
Adjustment Scale.
The secondary (exploratory) aim will focus on deter-
mining patient factors associated with variation in pri-
mary or secondary outcomes. In particular, similar linear
mixed-effect and GLM models will be run as described
above, but including patient baseline factors such as
mood disorder diagnosis, presence of substance use dis-
orders, and provider type (e.g., solo or small group prac-
tice) as potential covariates that might explain outcome
differences (if any) between those randomized to receive
CCM or usual care.
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lysis from the payer perspective involving a comparison of
utilization costs of health service providers including the
care manager’s time ascertained from time-motion survey.
Generalized Linear Models with log link functions will be
used to correct for heteroscedasticity and reduce the impact
of outliers (Manning & Mullahy 2001). The incremental ef-
fectiveness of CCM compared to usual care will be mea-
sured by changes in health utilities, assessed using a
method described by Zivin (Zivin et al. 2008) and Brazier
(Brazier et al. 2005) which translates six of the SF-12 items
to changes in health utility (SF-6) based on responses to
standard gamble questions given by community members
regarding all combinations of possible health states. Cost-
effectiveness ratios will be calculated based on the differ-
ence in per patient costs and effectiveness of CCM versus
usual care. To quantify uncertainty around these ratios, a
standard nonparametric bootstrapping approach will be
employed. For the business case, additional analyses will be
conducted in which changes over time in utilization and
costs of inpatient, ER, and outpatient services (medical,
psychiatric) will be compared between patients in the CCM
or usual care arms over a 2-year period, in order to deter-
m i n et h et i m ed y n a m i c sb yw h i c ht h eC C Ml e dt oc h a n g e s
in health care costs.
Sample size and power
The study sample size was estimated based on our pri-
mary aim and informed by our updated CCM pilot studies
that estimate effects on changes in the most conservative
outcome change to be expected (Cohen’s D=.36 based on
changes in PHQ-9 symptom scores and Cohen’sD = . 3 1
based on changes in SF-12 MCS scores from baseline to
12 months). Assuming a 20% dropout by 12 months, a
projected 172 patients enrolled per arm (344 patients total
per arm) would provide 82.5% power (two-sided alpha
test) to detect the expected between-group difference in
mean outcome scores assuming one or two patients per
provider with a 0.05 within-provider correlation, and ad-
justment for multiple comparisons (Bauer et al. 2009).
Trial status
Staff training and finalization of recruitment procedures
occurred in the spring of 2014. Recruitment and CCM
implementation will begin by fall of 2014. Recruitment is
anticipated to last 18 months, hence allowing for ample
time to recruit patients with either bipolar disorder or
depression. Years 3-5 will be devoted to follow up data,
analyses for secondary aims, as well as study dissemin-
ation and implementation activities.
Discussion
We describe to date one of the first studies to implement
a CCM at in a nationwide health plan for patients from
small practices, where most mood disorders are seen.
CCMs have mostly been implemented at the facility level,
and primarily developed for and adopted by larger health-
care organizations. Implementation of evidence-based
practices such as the CCM at the health plan level is es-
sential in order to further spread these effective programs
to those who need them the most.
Between 50-70% of Americans with mood disorders are
managed by commercial insurance plans such as Aetna. A
focused implementation of a cross-diagnosis CCM at the
national level has implications for the tailoring of evidence-
based programs to smaller and rural settings, personalized
health care, and implementation of health information
technology. As technologies around large databases be-
come more sophisticated and complete, implementation
programs that successfully apply these rich resources to
helping vulnerable populations will serve as important
milestones in the nation’s transition to a more public
health model of care.
This study involves a number of strengths, including a
groundbreaking health plan- academic partnership, com-
prehensive data sources, and emphasis on smaller and
solo practices. By focusing on measurement dimensions
of the Berwick Triple Aim (care, health, and cost), this
proposed study is potentially generalizable across com-
plex patient populations (Berwick et al. 2008). Nonethe-
less, there are key limitations of this proposed design to
consider. In addition, while many persons with mood
disorders are privately insured under network-model
HMOs such as Aetna (Frank et al. 2003), the potential
generalizability of this study is restricted to individuals
with network-model health plan insurance. This study
nonetheless complements a number of initiatives in the
public sector that are currently being implemented to
increase the uptake of CCMs for mental disorders such
as health homes (Collins et al. 2010). Finally, the cost ef-
fectiveness analysis is exploratory and not fully powered,
but will nonetheless provide valuable information for or-
ganizations considering its further adoption.
Conclusions
Health plan-level CCMs can potentially increase access to
evidence –based care and improve outcomes for persons
with mood disorders seen by solo or small group practices.
This proposed study takes advantage of a unique partner-
ship with a national health plan (Aetna) to develop and im-
plement a CCM designed to improve outcomes for persons
with mood disorders for solo or small practices, with an
eye towards developing a business case for a generalizable
plan-level CCM for chronic disorders. This study will con-
tribute to the evolution of the business case for CCMs in
general and enhance the utility of plan-level panel man-
agement focused on vulnerable populations across differ-
ent treatment settings.
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